Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trialYi‐Long Wu, Tae Min Kim, Valentina Guarneri et al.|The Lancet Oncology|2024Cited by 98
Exposure–response analyses for the MET inhibitor tepotinib including patients in the pivotal VISION trial: support for dosage recommendationsWenyuan Xiong, Rainer Strotmann, Andreas Johne et al.|Cancer Chemotherapy and Pharmacology|2022Cited by 12